Skip to main content
N4 PHARMA PLC logo

N4 PHARMA PLC — Investor Relations & Filings

Ticker · N4P ISIN · GB00BYW8QM32 LEI · 213800I841D2RKMFK955 IL Professional, scientific and technical activities
Open in API
Filings indexed 840 across all filing types
Latest filing 2021-02-11 Regulatory Filings
Country GB United Kingdom
Listing IL N4P

About N4 PHARMA PLC

https://n4pharma.com/

N4 Pharma PLC is a specialist pharmaceutical company focused on the development of Nuvec®, its proprietary silica nanoparticle delivery system. This platform technology is designed to enhance the cellular delivery and potency of nucleic acid-based treatments, such as vaccines and cancer therapies. The company's primary focus is on applying Nuvec® to enable advanced therapies for oncology and infectious diseases. N4 Pharma's business model involves developing and out-licensing its technology to pharmaceutical and biotechnology partners to improve the performance of new and existing drugs.

Recent filings

Filing Released Lang Actions
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document is very short (1914 characters) and contains the header 'RNS Number : 8616O'. It announces a 'Price Monitoring Extension' related to trading on the London Stock Exchange and explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' This structure—a brief announcement disseminated via the RNS system, often concerning market operations rather than comprehensive financial results or statutory reports—fits best under the general Regulatory Filings category, as it is a specific market notice that doesn't align with the more detailed definitions like 10-K, ER, or IR. Since RNS is the source and the content is a specific market operational update, RNS is the most appropriate classification.
2021-02-11 English
Second Price Monitoring Extn
Regulatory Filings Classification · 1% confidence The document is very short (1931 characters) and contains the header 'RNS Number : 8455O'. It announces a 'Second Price Monitoring Extension' related to trading activity on the London Stock Exchange. The text explicitly mentions RNS as the news service approved by the Financial Conduct Authority (FCA) for providing primary information in the UK. This type of immediate, brief regulatory update that doesn't fit a specific financial reporting category (like 10-K, ER, or DIV) is best classified as a general Regulatory Filing or Announcement, which corresponds to the RNS code.
2021-02-11 English
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document begins with 'RNS Number' and is distributed via 'RNS, the news service of the London Stock Exchange.' The content describes a 'Price Monitoring Extension' for a security, which is a specific, short-form regulatory announcement related to trading procedures, not a comprehensive financial report or a standard corporate action like a dividend or management change. Since it is a general regulatory announcement originating from the London Stock Exchange's news service (RNS) and does not fit into the more specific categories (like DIV, ER, 10-K, etc.), the most appropriate classification is the general regulatory filing fallback category.
2021-02-11 English
Second Price Monitoring Extn
Regulatory Filings Classification · 1% confidence The document is very short (1931 characters) and contains the header 'RNS Number : 8189O'. It announces a 'Second Price Monitoring Extension' related to trading activity, which is a specific operational announcement. The text explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' This strongly indicates it is a general regulatory announcement that does not fit into the more specific categories like ER, 10-K, or DIV. Therefore, the most appropriate classification is the general regulatory filing fallback category.
2021-02-11 English
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document explicitly starts with 'RNS Number' and mentions 'RNS, the news service of the London Stock Exchange' and 'Financial Conduct Authority'. The content describes a 'Price Monitoring Extension' related to trading rules, which is a specific, non-financial report announcement. Since it is a general regulatory announcement distributed via the RNS system and does not fit into the specific categories like 10-K, ER, or DIV, the most appropriate classification is the general regulatory filing category.
2021-02-11 English
Notification of Intention to Grant Patent
Regulatory Filings Classification · 1% confidence The document is a formal announcement disseminated via RNS (Regulatory News Service), indicated by the 'RNS Number' header and the concluding boilerplate text referencing RNS and the London Stock Exchange. The content announces a specific corporate event: the 'Notification of Intention to Grant Patent' by the European Patent Office (EPO) concerning the company's Nuvec® technology. This is a specific, material corporate update that is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA). Since it is a formal, non-standard regulatory announcement that doesn't fit the more specific categories like DIRS, DIV, or CAP, it falls best under the general regulatory announcement category, RNS, which serves as the fallback for miscellaneous regulatory filings.
2021-02-11 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.